Medicare payment in January helps MD Anderson reduce its operating losses

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MD Anderson Cancer Center reduced its year-to-date operating loss to $77.3 million in January, the fifth month of the fiscal year.

In January, the cumulative operating loss was $169.4 million. The loss shrunk because in January MD Anderson booked about $63.4 million in a settlement from Medicare, which allowed the cancer center to claim a portion of its expenses for implementing the Epic system.

Due to increased clinical activity by about 10 percent from December to January, operating revenues were around $28.7 million. This the first monthly positive margin since Epic’s rollout in March 2016.

In an interview with The Cancer Letter, MD Anderson Chief Operating Officer Steve Hahn said the installation, which he described as the largest in the history of Epic, changed over the cancer center’s inpatient, outpatient and billing systems at the same time.

Hahn, deputy to the president, said the installation of Epic exposed and exacerbated inefficiencies in the cancer center’s operations.

The text of the interview with Hahn appears here.

The cancer center’s financials appear below:

MD Anderson Cancer Center Monthly Financials,
September 2016 to January 2017

MDACC-1

Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login